Several other equities research analysts have also weighed in on the company. Zacks Investment Research lowered Cardiff Oncology from a hold rating to a sell rating in a report on Wednesday, March 2nd. Maxim Group cut their target price on Cardiff Oncology from $25.00 to $14.00 in a research note on Monday, January 24th. Finally, HC Wainwright cut their target price on Cardiff Oncology from $25.00 to $22.00 in a research note on Monday, May 9th. One investment analyst has rated the stock with a sell rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of Buy and an average target price of $13.00.
Shares of CRDF opened at $1.34 on Tuesday. The business has a 50-day moving average of $1.99 and a 200 day moving average of $3.90. Cardiff Oncology has a fifty-two week low of $1.13 and a fifty-two week high of $9.07. The firm has a market cap of $58.03 million, a P/E ratio of -1.63 and a beta of 2.04.
Institutional investors and hedge funds have recently modified their holdings of the company. Citigroup Inc. boosted its position in shares of Cardiff Oncology by 105.1% during the 4th quarter. Citigroup Inc. now owns 10,574 shares of the company’s stock valued at $64,000 after acquiring an additional 5,419 shares during the last quarter. Metropolitan Life Insurance Co NY bought a new stake in shares of Cardiff Oncology during the 3rd quarter valued at about $74,000. Invesco Ltd. bought a new stake in shares of Cardiff Oncology during the 2nd quarter valued at about $87,000. HighVista Strategies LLC bought a new stake in shares of Cardiff Oncology during the 3rd quarter valued at about $103,000. Finally, GSA Capital Partners LLP bought a new stake in shares of Cardiff Oncology during the 4th quarter valued at about $93,000. Hedge funds and other institutional investors own 56.43% of the company’s stock.
About Cardiff Oncology (Get Rating)
Cardiff Oncology, Inc, a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; metastatic colorectal cancer that is in clinical trials; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.
- Get a free copy of the StockNews.com research report on Cardiff Oncology (CRDF)
- The Three Most Upgraded Stocks You Can Buy Now
- MarketBeat: Week in Review 5/9 – 5/13
- Is Electronic Arts (NASDAQ: EA) Suddenly A Safe Haven?
- Beyond Meat Stock Value is Improving
- The Travel Sector Is Getting Upgraded
Receive News & Ratings for Cardiff Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiff Oncology and related companies with MarketBeat.com's FREE daily email newsletter.